Subject Predicate Object
MrpLNGiU
a
Resource
Answer
Written answer
answer has question
15rjLomc
answer has answering person
Stephen Charles Brine
answer text
<p>The National Institute for Health and Care Excellence (NICE) is able to take into account the commercial terms offered by a manufacturer during a NICE appraisal through a mechanism known as a commercial access agreement. On two occasions NICE has issued optimised recommendations to make rare disease medicines routinely available for the appropriate group of National Health Service patients that are conditional on it being supplied in accordance with the terms of the commercial access arrangements. These were Sorafenib, for advanced hepatocellular carcinoma, and ibrutinib for relapsed or refractory mantle cell lymphoma.</p><p> </p><p>This is different from the process of a conditional recommendation for use within the Cancer Drugs Fund (CDF) for oncology drugs, where there is significant remaining clinical uncertainty which needs more investigation through data collection. In these cases funding is provided from the CDF for a time-limited period to allow patient access whilst this data is collected, before guidance is then reviewed again for routine commissioning.</p><p> </p><p>NICE does not have any particular criteria to determine whether treatments are eligible for conditional recommendations. However, the process guide for patient access schemes and commercial access agreements and the CDF can be found at the following link:</p><p><a href="https://www.nice.org.uk/process/pmg19/chapter/patient-access-schemes-commercial-access-agreements-and-flexible-pricing" target="_blank">https://www.nice.org.uk/process/pmg19/chapter/patient-access-schemes-commercial-access-agreements-and-flexible-pricing</a></p>
answer given date
answer has answering body
Department of Health and Social Care
written answer has answering body
Department of Health and Social Care
Department of Health and Social Care
answering body has written answer
MrpLNGiU
answering body has answer
MrpLNGiU
15rjLomc
question has answer
MrpLNGiU
Stephen Charles Brine
answering person has answer
MrpLNGiU